Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions
Iain McGill discusses the company's clinical stage liver transplant program, as well as the IBD and type 1 diabetes programs that earned Quell a partnership with AstraZeneca.